Patents Examined by James H. Alstrum-Acevedo
  • Cancer specific lipid targeted peptidomimetics
    Patent number: 10849875
    Abstract: A phosphatidylserine targeted peptoid has been identified with the ability to bind to cancer cells globally and specifically. A dimer of the peptoid decreases cancer cell viability. Use of the dimerized peptoid enhances the efficacy of docetaxel. The peptoid can be used for including but not limited to diagnosing and treating cancer, diagnosing and treating a viral condition, and diagnosing and treating diabetes.
    Type: Grant
    Filed: July 23, 2016
    Date of Patent: December 1, 2020
    Assignees: University of Houston System, Board of Regents of The University of Texas System
    Inventors: Damith Gomika Udugamasooriya, Rolf A. Brekken
  • Peptide compounds to regulate the complement system
    Patent number: 10844093
    Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: November 24, 2020
    Assignee: REALTA HOLDINGS, LLC
    Inventors: Neel K. Krishna, Kenji Cunnion
  • Biosynthetic proline/alanine random coil polypeptides and their uses
    Patent number: 10844094
    Abstract: The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) fconstituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 24, 2020
    Assignees: TECHNISCHE UNIVERSITÄT MÜNCHEN, XL-PROTEIN GMBH
    Inventors: Arne Skerra, Uli Binder, Martin Schlapschy
  • Peptide for promoting regeneration of dentin or dental pulp tissue
    Patent number: 10844092
    Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: November 24, 2020
    Assignee: HysensBio Co., Ltd.
    Inventors: Joohwang Park, Jihyun Lee
  • Hemiasterlin derivatives for conjugation and therapy
    Patent number: 10844090
    Abstract: Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W1, W4, W5, SG, and R are as described herein.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 24, 2020
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Toni Kline, Qun Yin, Krishna Bajjuri
  • Relaxin for treating patients afflicted of impaired glucose tolerance
    Patent number: 10842851
    Abstract: A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 24, 2020
    Assignee: Immundiagnostik AG
    Inventor: Thomas Dschietzig
  • Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
    Patent number: 10844102
    Abstract: Peptides that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: November 24, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Biodegradable injectable gel
    Patent number: 10835637
    Abstract: The present invention relates to a triblock copolymer having a polyethylene glycol-poly(D,L-lactide)-polyethylene glycol skeleton.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 17, 2020
    Assignees: 3-D Matrix, Ltd. (Tokyo, Japan), Tokyo University of Science Foundation
    Inventors: Hidenori Otsuka, Daisuke Matsukuma, Noriaki Matsuda
  • Elevated intracranial pressure treatment
    Patent number: 10835579
    Abstract: Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 17, 2020
    Assignee: INVEX THERAPEUTICS LTD.
    Inventor: Alex Sinclair
  • Analogues of VDAC1-derived peptides
    Patent number: 10829530
    Abstract: The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: November 10, 2020
    Assignees: B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY, THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD. BEN-GURION UNIVERSITY OF THE NEGEV
    Inventor: Varda Shoshan-Barmatz
  • Bone formation promoter
    Patent number: 10821136
    Abstract: The present invention provides a bone formation promoter having high biological safety and capable of promoting bone formation. The bone formation promoter of the present invention includes a self-assembling peptide capable of forming a ?-sheet structure in an aqueous solution having a neutral pH; and a bone chip. A sum of charges of amino acid residues constituting the self-assembling peptide at pH 7.0 is unequal to 0.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: November 3, 2020
    Assignees: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM, MENICON CO., LTD.
    Inventors: Kei Ando, Naoki Ishiguro, Shiro Imagama, Zenya Ito, Yasuhiro Yokoyama, Hidenori Yokoi, Yusuke Nagai
  • Methods and compositions for modulating toso activity
    Patent number: 10822388
    Abstract: The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: November 3, 2020
    Assignee: University Health Network
    Inventors: Michael W. Tusche, Tak W. Mak, Pamela S. Ohashi, Philipp Lang, Karl Lang, Dirk Brenner, Gloria Lin
  • Infant nutrition for improvement in insulin sensitivity later in life
    Patent number: 10821150
    Abstract: The present invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life, wherein the nutritional composition comprises casein.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: November 3, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Florence Blancher, Catherine Mace, Yassaman Shahkhalili Dulloo
  • Methods, agents and compositions for treatment of inflammatory conditions
    Patent number: 10821152
    Abstract: The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g. rheumatoid arthritis or spondyloarthritis) or patients with inflammatory peripheral GnRH with GnRH antagonists or drugs that lower the effects of GnRH.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 3, 2020
    Assignee: BETANIEN HOSPITAL
    Inventor: Anita Kåss
  • CD31 peptides
    Patent number: 10815272
    Abstract: The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: October 27, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertensions, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders
    Patent number: 10806775
    Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: October 20, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Henry Daniell
  • Compound with effects of thrombolysis, free radical scavenging and thrombus-targeting
    Patent number: 10806798
    Abstract: The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: October 20, 2020
    Assignee: Shanghai Lumosa Therapeutics Co., Ltd.
    Inventors: Shiqi Peng, Ming Zhao, Xueyun Jiang
  • TFPI inhibitors and methods of use
    Patent number: 10800816
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: October 13, 2020
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
  • Modulation of structured polypeptide specificity
    Patent number: 10800813
    Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: October 13, 2020
    Assignee: BICYCLERD LIMITED
    Inventors: John Tite, Edward Walker, Catherine Stace, Daniel Teufel
  • Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes
    Patent number: 10799442
    Abstract: Compounds of general formula (I): R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 13, 2020
    Assignee: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Nuria Alminana Domenech, Wim Van Den Nest, Maria Del Carmen Lidon, Antonio Ferrer Montiel